{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T14:59:51Z","timestamp":1791644391286,"version":"4.3.4"},"reference-count":91,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T00:00:00Z","timestamp":1788739200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>\n                    Interleukin-10 (IL-10) is classically defined as a potent anti-inflammatory cytokine that protects tissues by constraining myeloid activation and limiting inflammatory cytokine production. Yet, accumulating evidence indicates that, in defined contexts, IL-10 can also promote antitumor immunity by enhancing the fitness and cytotoxic programs of CD8\n                    <jats:sup>+<\/jats:sup>\n                    T cells and natural killer (NK) cells. Conversely, in other tumor contexts, IL-10 may reinforce immunosuppressive myeloid and regulatory programs, and the factors that determine these divergent outcomes remain incompletely understood. Although these effects converge on a common JAK1\/TYK2\u2013STAT3 signaling hub, the downstream biological outcomes are combinatorially shaped by the identity, activation, and chromatin state of the responding cell, co-engaged pathways, including STAT1, mTORC1, and NF-\u03baB\/AP, receptor abundance, feedback regulation, and the surrounding microenvironment. Recent studies suggest IL-10 can sustain cytotoxic lymphocyte function under tumor microenvironmental stress through effector programming, restraint of terminal exhaustion, mitochondrial metabolic reprogramming, and remodeling of the tumor microenvironment (TME). However, several of these mechanisms remain supported primarily by limited preclinical models and correlative human data. These advances have promoted the development of pharmacokinetically optimized IL-10 variants, tumor-targeted immunocytokines, surrogate bispecific IL-10 receptor agonists, and IL-10\u2013armored adoptive cell therapies. Although several approaches have shown immune activation and preliminary antitumor activity in early-phase studies, pegilodecakin\u2014the only IL-10-based agent to complete a randomized phase III oncology trial\u2014did not improve survival in gemcitabine-refractory pancreatic cancer, underscoring the gap between pharmacodynamic activity and established clinical benefit. In this review, we synthesize mechanistic and translational advances with conflicting and cautionary evidence, discuss safety considerations associated with IL-10-based agents and IL-10-armored cell therapies, and propose a context-dependent framework for their further development based on tumor and microenvironmental features, spatiotemporal control, rational combination strategies, and candidate biomarkers.\n                  <\/jats:p>","DOI":"10.3389\/fimmu.2026.1898790","type":"journal-article","created":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T13:15:32Z","timestamp":1788786932000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["IL-10\u2019s contextual role in cytotoxic antitumor immunity: evidence, controversies, and therapeutic translation"],"prefix":"10.3389","volume":"17","author":[{"given":"Minchuan","family":"Zhang","sequence":"first","affiliation":[{"name":"Singapore Immunology Network, Agency for Science, Technology, and Research","place":["Singapore, Singapore"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi-Jing","family":"Li","sequence":"additional","affiliation":[{"name":"Institute of Molecular and Cell Biology, Agency for Science, Technology, and Research","place":["Singapore, Singapore"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kong Peng","family":"Lam","sequence":"additional","affiliation":[{"name":"Singapore Immunology Network, Agency for Science, Technology, and Research","place":["Singapore, Singapore"]},{"name":"Department of Microbiology and Immunology, Yong Loo Lin School of Medicine, National University of Singapore","place":["Singapore, Singapore"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengli","family":"Xu","sequence":"additional","affiliation":[{"name":"Singapore Immunology Network, Agency for Science, Technology, and Research","place":["Singapore, Singapore"]},{"name":"Department of Physiology, Yong Loo Lin School of Medicine, National University of Singapore","place":["Singapore, Singapore"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1146\/annurev-immunol-031210-101312","article-title":"Regulation and functions of the IL-10 family of cytokines in inflammation and disease","volume":"29","author":"Ouyang","year":"2011","journal-title":"Annu Rev Immunol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"a028548","DOI":"10.1101\/cshperspect.a028548","article-title":"Targeting IL-10 family cytokines for the treatment of human diseases","volume":"11","author":"Wang","year":"2019","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2019.03.020","article-title":"IL-10 family cytokines IL-10 and IL-22: from basic science to clinical translation","volume":"50","author":"Ouyang","year":"2019","journal-title":"Immunity"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2011.11.003","article-title":"IL-10 elicits IFN\u03b3-dependent tumor immune surveillance","volume":"20","author":"Mumm","year":"2011","journal-title":"Cancer Cell"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.619195","article-title":"IL-10 enhances human natural killer cell effector functions via metabolic reprogramming regulated by mTORC1 signaling","volume":"12","author":"Wang","year":"2021","journal-title":"Front Immunol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.can-12-0721","article-title":"IL-10 directly activates and expands tumor-resident CD8(+) T cells without de novo infiltration from secondary lymphoid organs","volume":"72","author":"Emmerich","year":"2012","journal-title":"Cancer Res"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1089\/jir.2014.0221","article-title":"The potentiation of IFN-\u03b3 and induction of cytotoxic proteins by pegylated IL-10 in human CD8 T cells","volume":"35","author":"Chan","year":"2015","journal-title":"J Interferon Cytokine Res"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2016.68.1106","article-title":"Safety, antitumor activity, and immune activation of pegylated recombinant human interleukin-10 (AM0010) in patients with advanced solid tumors","volume":"34","author":"Naing","year":"2016","journal-title":"J Clin Oncol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1016\/j.ccell.2018.10.007","article-title":"PEGylated IL-10 (Pegilodecakin) induces systemic immune activation, CD8(+) T cell invigoration and polyclonal T cell expansion in cancer patients","volume":"34","author":"Naing","year":"2018","journal-title":"Cancer Cell"},{"key":"B10","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.immuni.2018.01.006","article-title":"Interleukin-10 directly inhibits CD8(+) T cell function by enhancing N-glycan branching to decrease antigen sensitivity","volume":"48","author":"Smith","year":"2018","journal-title":"Immunity"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-024-02391-8","article-title":"IL-10R inhibition reprograms tumor-associated macrophages and reverses drug resistance in multiple myeloma","volume":"38","author":"Sun","year":"2024","journal-title":"Leukemia"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2015.07.009","article-title":"The paradoxical role of IL-10 in immunity and cancer","volume":"367","author":"Mannino","year":"2015","journal-title":"Cancer Lett"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellimm.2014.12.012","article-title":"Manipulating IL-10 signalling blockade for better immunotherapy","volume":"293","author":"Ni","year":"2015","journal-title":"Cell Immunol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s12026-009-8150-5","article-title":"Cell type-specific regulation of IL-10 expression in inflammation and disease","volume":"47","author":"Hedrich","year":"2010","journal-title":"Immunol Res"},{"key":"B15","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/s1471-4906(02)00009-1","article-title":"The dual role of IL-10","volume":"24","author":"Mocellin","year":"2003","journal-title":"Trends Immunol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1177\/1010428317706209","article-title":"Stimulatory role of interleukin 10 in CD8(+) T cells through STATs in gastric cancer","volume":"39","author":"Xi","year":"2017","journal-title":"Tumour Biol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"2825","DOI":"10.1016\/j.immuni.2021.11.004","article-title":"Interleukin-10 receptor signaling promotes the maintenance of a PD-1(int) TCF-1(+) CD8(+) T cell population that sustains anti-tumor immunity","volume":"54","author":"Hanna","year":"2021","journal-title":"Immunity"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2319254121","article-title":"Fatty acid oxidation fuels natural killer cell responses against infection and cancer","volume":"121","author":"Sheppard","year":"2024","journal-title":"Proc Natl Acad Sci"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-021-00940-2","article-title":"Metabolic reprogramming of terminally exhausted CD8+ T cells by IL-10 enhances anti-tumor immunity","volume":"22","author":"Guo","year":"2021","journal-title":"Nat Immunol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2025.102257","article-title":"Coupling IL-2 with IL-10 to mitigate toxicity and enhance antitumor immunity","volume":"6","author":"Ahn","year":"2025","journal-title":"Cell Rep Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2023.101154","article-title":"A CSF-1R-blocking antibody\/IL-10 fusion protein increases anti-tumor immunity by effectuating tumor-resident CD8+ T cells","volume":"4","author":"Chang","year":"2023","journal-title":"Cell Rep Med"},{"key":"B22","doi-asserted-by":"publisher","first-page":"5544\u2013","DOI":"10.1158\/1538-7445.am2022-5544","article-title":"Abstract 5544: IL10\/IL2 surrogate cytokine agonists","volume":"82","author":"Ramadass","year":"2022","journal-title":"Cancer Res"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1200\/jco.20.02232","article-title":"Randomized phase III study of FOLFOX alone or with Pegilodecakin as second-line therapy in patients with metastatic pancreatic cancer that progressed after gemcitabine (SEQUOIA)","volume":"39","author":"Hecht","year":"2021","journal-title":"J Clin Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.cir-13-0214","article-title":"IL-10: master switch from tumor-promoting inflammation to antitumor immunity","volume":"2","author":"Oft","year":"2014","journal-title":"Cancer Immunol Res"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/nri2711","article-title":"The regulation of IL-10 production by immune cells","volume":"10","author":"Saraiva","year":"2010","journal-title":"Nat Rev Immunol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1161067","article-title":"The multifaceted nature of IL-10: regulation, role in immunological homeostasis and its relevance to cancer, COVID-19 and post-COVID conditions","volume":"14","author":"Carlini","year":"2023","journal-title":"Front Immunol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.160.6.2637","article-title":"Production of IL-10 by human natural killer cells stimulated with IL-2 and\/or IL-12","volume":"160","author":"Mehrotra","year":"1998","journal-title":"J Immunol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"e20190418","DOI":"10.1084\/jem.20190418","article-title":"Biology and therapeutic potential of interleukin-10","volume":"217","author":"Saraiva","year":"2020","journal-title":"J Exp Med"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1111\/j.0105-2896.2009.00855.x","article-title":"Suppressive functions of activated B cells in autoimmune diseases reveal the dual roles of Toll-like receptors in immunity","volume":"233","author":"Lampropoulou","year":"2010","journal-title":"Immunol Rev"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0900270","article-title":"The development and function of regulatory B cells expressing IL-10 (B10 cells) requires antigen receptor diversity and TLR signals","volume":"182","author":"Yanaba","year":"2009","journal-title":"J Immunol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.970906","article-title":"IL-10 revisited in systemic lupus erythematosus","volume":"13","author":"Biswas","year":"2022","journal-title":"Front Immunol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-065x.2008.00711.x","article-title":"Diversity in the contribution of interleukin-10 to T-cell-mediated immune regulation","volume":"226","author":"Maynard","year":"2008","journal-title":"Immunol Rev"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/ni.1996","article-title":"CD4+ T cell help and innate-derived IL-27 induce Blimp-1-dependent IL-10 production by antiviral CTLs","volume":"12","author":"Sun","year":"2011","journal-title":"Nat Immunol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1003292","article-title":"Highly activated cytotoxic CD8 T cells express protective IL-10 at the peak of coronavirus-induced encephalitis","volume":"186","author":"Trandem","year":"2011","journal-title":"J Immunol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1007\/978-3-662-43492-5_9","article-title":"The molecular basis of IL-10 function: from receptor structure to the onset of signaling","volume":"380","author":"Walter","year":"2014","journal-title":"Curr Top Microbiol Immunol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.275.18.13552","article-title":"Design and analysis of an engineered human interleukin-10 monomer","volume":"275","author":"Josephson","year":"2000","journal-title":"J Biol Chem"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.str.2010.02.009","article-title":"Structure and mechanism of receptor sharing by the IL-10R2 common chain","volume":"18","author":"Yoon","year":"2010","journal-title":"Structure"},{"key":"B38","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/B978-0-12-800267-4.00005-5","article-title":"Interleukin 10 receptor signaling: master regulator of intestinal mucosal homeostasis in mice and humans","volume":"122","author":"Shouval","year":"2014","journal-title":"Adv Immunol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1111\/febs.16207","article-title":"Cryo-EM structure of the IL-10 receptor complex provides a blueprint for ligand engineering","volume":"289","author":"Saxton","year":"2022","journal-title":"FEBS J"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0186317","article-title":"Re-evaluation of IL-10 signaling reveals novel insights on the contribution of the intracellular domain of the IL-10R2 chain","volume":"12","author":"Wilbers","year":"2017","journal-title":"PloS One"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1093\/bfgp\/elt028","article-title":"The IL-10\/STAT3-mediated anti-inflammatory response: recent developments and future challenges","volume":"12","author":"Hutchins","year":"2013","journal-title":"Brief Funct Genomics"},{"key":"B42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cytogfr.2016.05.001","article-title":"STAT3 signaling in immunity","volume":"31","author":"Hillmer","year":"2016","journal-title":"Cytokine Growth Factor Rev"},{"key":"B43","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/s1074-7613(00)80005-9","article-title":"Enhanced Th1 activity and development of chronic enterocolitis in mice devoid of Stat3 in macrophages and neutrophils","volume":"10","author":"Takeda","year":"1999","journal-title":"Immunity"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/s0014-5793(00)01905-0","article-title":"IL-10 attenuates IFN-\u03b1-activated STAT1 in the liver: involvement of SOCS2 and SOCS3","volume":"480","author":"Shen","year":"2000","journal-title":"FEBS Lett"},{"key":"B45","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1016\/j.cell.2022.02.025","article-title":"Facile discovery of surrogate cytokine agonists","volume":"185","author":"Yen","year":"2022","journal-title":"Cell"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.271.28.16485","article-title":"In vivo regulation of murine granzyme B gene transcription in activated primary T cells","volume":"271","author":"Babichuk","year":"1996","journal-title":"J Biol Chem"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.176.7.4173","article-title":"A novel NF-\u03baB binding site controls human granzyme B gene transcription","volume":"176","author":"Huang","year":"2006","journal-title":"J Immunol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/j.cytogfr.2009.11.005","article-title":"Dangerous liaisons: STAT3 and NF-\u03baB collaboration and crosstalk in cancer","volume":"21","author":"Grivennikov","year":"2010","journal-title":"Cytokine Growth Factor Rev"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1186\/1756-8935-8-7","article-title":"STAT3 acts through pre-existing nucleosome-depleted regions bound by FOS during an epigenetic switch linking inflammation to cancer","volume":"8","author":"Fleming","year":"2015","journal-title":"Epigenet Chromatin"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.am2017-654","article-title":"The epigenetic landscape of T cell exhaustion","volume":"354","author":"Sen","year":"2016","journal-title":"Science"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1093\/cei\/uxac040","article-title":"The clinical, molecular, and therapeutic features of patients with IL10\/IL10R deficiency: a systematic review","volume":"208","author":"Sharifinejad","year":"2022","journal-title":"Clin Exp Immunol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1038\/srep42791","article-title":"Interleukin 10 inhibits pro-inflammatory cytokine responses and killing of Burkholderia pseudomallei","volume":"7","author":"Kessler","year":"2017","journal-title":"Sci Rep"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1038\/nri2097","article-title":"TH1 cells control themselves by producing interleukin-10","volume":"7","author":"O'Garra","year":"2007","journal-title":"Nat Rev Immunol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2011.07.010","article-title":"CD8(+) T cells: foot soldiers of the immune system","volume":"35","author":"Zhang","year":"2011","journal-title":"Immunity"},{"key":"B55","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1615\/critrevimmunol.v32.i1.30","article-title":"Role of interleukin 10 transcriptional regulation in inflammation and autoimmune disease","volume":"32","author":"Iyer","year":"2012","journal-title":"Crit Rev Immunol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1684\/ecn.2010.0201","article-title":"Protective and detrimental roles of IL-10 in HIV pathogenesis","volume":"21","author":"Kwon","year":"2010","journal-title":"Eur Cytokine Netw"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2893.2010.01335.x","article-title":"Early IL-10 predominant responses are associated with progression to chronic hepatitis C virus infection in injecting drug users","volume":"18","author":"Flynn","year":"2011","journal-title":"J Viral Hepat"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1126\/science.2173142","article-title":"Expression of interleukin-10 activity by Epstein-Barr virus protein BCRF1","volume":"250","author":"Hsu","year":"1990","journal-title":"Science"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20071948","article-title":"IL-10 blockade facilitates DNA vaccine-induced T cell responses and enhances clearance of persistent virus infection","volume":"205","author":"Brooks","year":"2008","journal-title":"J Exp Med"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-06-508267","article-title":"A Mendelian predisposition to B-cell lymphoma caused by IL-10R deficiency","volume":"122","author":"Neven","year":"2013","journal-title":"Blood"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1172\/jci118861","article-title":"Enterocolitis and colon cancer in interleukin-10-deficient mice are associated with aberrant cytokine production and CD4(+) TH1-like responses","volume":"98","author":"Berg","year":"1996","journal-title":"J Clin Invest"},{"key":"B62","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1089\/hum.1996.7.1-23","article-title":"Loss of tumorigenicity and increased immunogenicity induced by interleukin-10 gene transfer in B16 melanoma cells","volume":"7","author":"G\u00e9rard","year":"1996","journal-title":"Hum Gene Ther"},{"key":"B63","doi-asserted-by":"publisher","first-page":"P204","DOI":"10.1186\/2051-1426-3-s2-p204","article-title":"CD8+ T cell stimulation with pegylated recombinant human IL-10 in the patient with advanced solid tumors - a Phase I study","volume":"3","author":"Naing","year":"2015","journal-title":"J Immunother Cancer"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1182\/blood.v85.12.3577.bloodjournal85123577","article-title":"The functional characterization of interleukin-10 receptor expression on human natural killer cells","volume":"85","author":"Carson","year":"1995","journal-title":"Blood"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1007\/s10059-011-1057-8","article-title":"IL-15-induced IL-10 increases the cytolytic activity of human natural killer cells","volume":"32","author":"Park","year":"2011","journal-title":"Mol Cells"},{"key":"B66","doi-asserted-by":"publisher","first-page":"111341","DOI":"10.2139\/ssrn.4618580","article-title":"Interleukin-10 gene intervention ameliorates liver fibrosis by enhancing the immune function of natural killer cells in liver tissue","volume":"127","author":"Chen","year":"2024","journal-title":"Int Immunopharmacol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200206140-00007","article-title":"Normalization of natural killer cell function and phenotype with effective anti-HIV therapy and the role of IL-10","volume":"16","author":"Parato","year":"2002","journal-title":"AIDS"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1038\/sj.gene.6364135","article-title":"IL-10 stimulatory effects on human NK cells explored by gene profile analysis","volume":"5","author":"Mocellin","year":"2004","journal-title":"Genes Immun"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-3083.2010.02435.x","article-title":"Interleukin-10 promotes NK cell killing of autologous macrophages by stimulating expression of NKG2D ligands","volume":"72","author":"Schulz","year":"2010","journal-title":"Scand J Immunol"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1182\/blood.v98.7.2143","article-title":"Interleukin-10 promotes the maintenance of antitumor CD8+ T-cell effector function in situ","volume":"98","author":"Fujii","year":"2001","journal-title":"Blood"},{"key":"B71","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/j.immuni.2011.09.017","article-title":"An interleukin-21-interleukin-10-STAT3 pathway is critical for functional maturation of memory CD8+ T cells","volume":"35","author":"Cui","year":"2011","journal-title":"Immunity"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23052878","article-title":"STAT3 role in T-cell memory formation","volume":"23","author":"Kaminskiy","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B73","doi-asserted-by":"publisher","first-page":"e20220686","DOI":"10.1084\/jem.20220686","article-title":"STAT3 regulates CD8+ T cell differentiation and functions in cancer and acute infection","volume":"220","author":"Sun","year":"2023","journal-title":"J Exp Med"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1101021","article-title":"IL-10 restricts activation-induced death of NK cells during acute murine cytomegalovirus infection","volume":"187","author":"Stacey","year":"2011","journal-title":"J Immunol"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/6104054","article-title":"IL-10: A multifunctional cytokine in viral infections","volume":"2017","author":"Rojas","year":"2017","journal-title":"J Immunol Res"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2024.03.010","article-title":"Immunometabolism of CD8+ T cell differentiation in cancer","volume":"10","author":"Shi","year":"2024","journal-title":"Trends Cancer"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-023-02060-8","article-title":"IL-10-expressing CAR T cells resist dysfunction and mediate durable clearance of solid tumors and metastases","volume":"42","author":"Zhao","year":"2024","journal-title":"Nat Biotechnol"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.20900\/immunometab20210030","article-title":"IL-10-mediated refueling of exhausted T cell mitochondria boosts anti-tumour immunity","volume":"3","author":"Ryan","year":"2021","journal-title":"Immunometabolism"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1016\/s2352-3026(25)00253-4","article-title":"IL-10-expressing, anti-CD19 CAR T cells for patients with relapsed or refractory B-cell acute lymphoblastic leukaemia: an open-label, single-arm, phase 1 study","volume":"12","author":"Xu","year":"2025","journal-title":"Lancet Haematology"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1080\/2162402x.2015.1014232","article-title":"IL-10 enhances CTL-mediated tumor rejection by inhibiting highly suppressive CD4(+) T cells and promoting CTL persistence in a murine model of plasmacytoma","volume":"4","author":"Wang","year":"2015","journal-title":"Oncoimmunology"},{"key":"B81","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1016\/j.ccell.2019.05.005","article-title":"Targeting tumors with IL-10 prevents dendritic cell-mediated CD8(+) T cell apoptosis","volume":"35","author":"Qiao","year":"2019","journal-title":"Cancer Cell"},{"key":"B82","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.3390\/cancers17061012","article-title":"IL-10-directed cancer immunotherapy: preclinical advances, clinical insights, and future perspectives","volume":"17","author":"El-Shemi","year":"2025","journal-title":"Cancers (Basel)"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1084\/jem.184.2.579","article-title":"Interleukin-10 inhibits tumor metastasis through an NK cell-dependent mechanism","volume":"184","author":"Zheng","year":"1996","journal-title":"J Exp Med"},{"key":"B84","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1006\/cimm.1997.1176","article-title":"Interleukin-10 inhibits tumor metastasis, downregulates MHC class I, and enhances NK lysis","volume":"180","author":"Kundu","year":"1997","journal-title":"Cell Immunol"},{"key":"B85","doi-asserted-by":"publisher","first-page":"e000131","DOI":"10.1136\/jitc-2019-000131","article-title":"CCL5-armed oncolytic virus augments CCR5-engineered NK cell infiltration and antitumor efficiency","volume":"8","author":"Li","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1002\/(sici)1097-0215(19990209)80:4<624::aid-ijc23>3.3.co;2-0","article-title":"Interleukin-10 gene transfer activates interferon-gamma and the interferon-gamma-inducible genes Gbp-1\/Mag-1 and Mig-1 in mammary tumors","volume":"80","author":"Sun","year":"1999","journal-title":"Int J Cancer"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1097\/00002371-200003000-00005","article-title":"Essential role of nitric oxide and interferon-gamma for tumor immunotherapy with interleukin-10","volume":"23","author":"Sun","year":"2000","journal-title":"J Immunother"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(19)30514-5","article-title":"Pegilodecakin combined with pembrolizumab or nivolumab for patients with advanced solid tumours (IVY): a multicentre, multicohort, open-label, phase 1b trial","volume":"20","author":"Naing","year":"2019","journal-title":"Lancet Oncol"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1080\/2162402x.2016.1197458","article-title":"PEG-rIL-10 treatment decreases FoxP3(+) Tregs despite upregulation of intratumoral IDO","volume":"5","author":"Chan","year":"2016","journal-title":"Oncoimmunology"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01794","article-title":"The generation of an engineered interleukin-10 protein with improved stability and biological function","volume":"11","author":"Minshawi","year":"2020","journal-title":"Front Immunol"},{"key":"B91","doi-asserted-by":"publisher","first-page":"eabc0653","DOI":"10.1126\/scisignal.abc0653","article-title":"Engineered IL-10 variants elicit potent immunomodulatory effects at low ligand doses","volume":"13","author":"Gorby","year":"2020","journal-title":"Sci Signal"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1898790\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T13:15:33Z","timestamp":1788786933000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1898790\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,7]]},"references-count":91,"alternative-id":["10.3389\/fimmu.2026.1898790"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1898790","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,7]]},"article-number":"1898790"}}